Call Us: +91-9915015108
Cefepime and Tazobactam are indicated as a parenteral therapy for the treatment of various moderate to severe forms of infections due to susceptible beta-lactamase producing microbial organisms. Cefepime and Tazobactam combination are particularly indicated if the Cefepime monotherapy is ineffective. Cefepime and Tazobactam are prescribed for the treatment of uncomplicated skin and skin structure infections, uncomplicated and complicated urinary tract infections (UTI) and complicated intra-abdominal infections in adults and children. Cefepime is a 4th generation cephalosporin.
Cefepime prevents final transpeptidation process of bacterial cell wall peptidoglycan biosynthesis. Cefepime binds with one or more penicillin-binding proteins (PBPs).
After intramuscular administration, Cefepime and Tazobactam is rapidly completed absorbed into the blood circulation. About 16-19% of Cefepime and Tazobactam are bound to plasma proteins. The Vss is 14-20 L. Cefepime and Tazobactam can pass through the blood brain barrier and inflammatory fluids. Cefepime and Tazobactam are mostly metabolized in the liver. The plasma half-life of Cefepime and Tazobactam is about 2 hours. The drug is mostly excreted in the urine as unchanged drug.
Cefepime binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, causing the inhibition of bacterial cell wall synthesis. Tazobactam is a beta lactamase inhibitor used to enhance activity of antibiotics by blocking bacterial beta-lactamases.
Cefepime and Tazobactam are contraindicated in patients with cephalosporin allergy, pregnancy, GI diseases including colitis, renal impairment, Clostridium-difficile associated diarrhoea, hepatic disorders and convulsion.
Cefepime and Tazobactam may interact with aminoglycosides and high-dose Probenecid.
